-
Loading metrics
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
-
Edward Wolin ,
Roles Data curation, Writing – review & editing
* E-mail: Edward.wolin@mssm.edu
Current address: Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, United States of America
Affiliation Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America
⨯ - Alain Mita,
- Amit Mahipal,
- Tim Meyer,
- Johanna Bendell,
- John Nemunaitis,
- Pam N. Munster,
- Luis Paz-Ares,
- Ellen H. Filvaroff,
- Shaoyi Li,
- Kristen Hege,
- Hans de Haan,
- Monica Mita
http://orcid.org/0000-0003-3992-8722
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
- Edward Wolin,
- Alain Mita,
- Amit Mahipal,
- Tim Meyer,
- Johanna Bendell,
- John Nemunaitis,
- Pam N. Munster,
- Luis Paz-Ares,
- Ellen H. Filvaroff,
- Shaoyi Li
x
- Published: September 17, 2019
- https://doi.org/10.1371/journal.pone.0221994